Two-Year Agility Maintenance Training Slows the Progression of Parkinsonian Symptoms

Med Sci Sports Exerc. 2019 Feb;51(2):237-245. doi: 10.1249/MSS.0000000000001793.

Abstract

Introduction: Parkinson's disease (PD) is a progressive neurodegenerative condition and it is unclear if long-term nonpharmaceutical interventions can slow the progression of motor and nonmotor symptoms and lower drug dose.

Methods: In a randomized trial, after an initial 3-wk-long, 15-session supervised high-intensity sensorimotor agility exercise (E) program designed to improve postural instability, the exercise+maintenance (E + M, n = 19) group continued to exercise three times per week for 2 yr, whereas E (n = 16), and the no exercise and no maintenance control (C, n = 20) continued habitual living. Eight outcomes were measured before and after the 3-wk initial exercise program and then at 3, 6, 9, 12, 18, and 24 months in all patients.

Results: The group-time interactions (all P < 0.005) revealed robust and favorable effects of the initial 3-wk agility program on all six nonmotor (e.g., primary outcome Movement Disorder Society Unified Parkinson Disease Rating Scale, Motor Experiences of Daily Living, ~7 points; EuroQoL, ~9 points) and on each of the two motor outcomes (timed up and go test: ~6 s; posturography: up to 7 mm improvements in center of pressure path). E + M maintained but did not further improve the benefits produced by the initial 3-wk program. In E, the favorable effects of the 3-wk agility program lasted for 3 to 12 months. In C, patients declined steadily in all outcomes over 2 yr. By year 2, Leva-dopa equivalents increased by 99.4 mg·d (time main effect, P = 0.008).

Conclusions: A high-intensity sensorimotor agility program with but not without a 2-yr maintenance program slowed the progression of parkinsonian symptoms.

Trial registration: ClinicalTrials.gov NCT03189680.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antiparkinson Agents / administration & dosage
  • Disease Progression
  • Exercise Therapy / methods*
  • Humans
  • Levodopa / administration & dosage
  • Middle Aged
  • Parkinson Disease / drug therapy
  • Parkinson Disease / therapy*
  • Postural Balance
  • Quality of Life
  • Treatment Outcome

Substances

  • Antiparkinson Agents
  • Levodopa

Associated data

  • ClinicalTrials.gov/NCT03189680